Learn how stem cell therapy for osteoarthritis and joint support promotes cartilage regeneration, reduces inflammation, and improves mobility. Personalized protocols using MSCs, iPSCs, chondrocytes, endothelial and neural cells, and exosomes deliver long-lasting results and may help avoid surgery.
Our innovative approach it stem cells therapy for osteoarthritis gives high success rate in clinical results.
1. What Is Osteoarthritis?
Osteoarthritis (OA) is a progressive degenerative joint disease that affects millions of people worldwide. It is characterized by the breakdown of articular cartilage — the smooth tissue that covers the ends of bones in joints — combined with inflammation of the synovial lining and changes in subchondral bone. This degeneration leads to pain, stiffness, limited mobility, swelling, and ultimately, impaired quality of life. Unlike acute injuries, OA reflects chronic tissue wear, cellular senescence, and failed regeneration of joint tissues.
Although OA can affect any joint, the knee, hip, hands, and spine are most commonly impacted. Cartilage has limited intrinsic ability to repair itself, because it lacks blood vessels and a robust population of stem cells. As a result, conventional therapies often fall short of reversing the disease process.
Traditional treatments for osteoarthritis are largely symptomatic rather than regenerative. Pain relievers, non‑steroidal anti‑inflammatory drugs (NSAIDs), physiotherapy, and corticosteroid injections aim to manage symptoms such as pain and inflammation but do not restore cartilage or reverse degeneration. In more advanced cases, joint replacement surgery may be recommended, but this approach is invasive and requires substantial recovery time.
Importantly, pain reduction with current treatments does not always correlate with long‑term improvements in cartilage structure or joint function. Because osteoarthritis involves multifactorial biological processes — including inflammation, extracellular matrix breakdown, cellular senescence, impaired tissue repair, and altered biomechanics — a holistic regenerative approach is increasingly sought.
GET MORE INFORMATION
The use of stem cells for joint therapy is not a new approach; it has been explored and applied clinically for over 20 years. Over this time, the field has continuously evolved, with new generations of bioactive products being developed and cultured to enhance regenerative potential. Each cohort of stem cells or exosomes is carefully optimized to improve cartilage repair, reduce inflammation, and maximize therapeutic outcomes, ensuring that patients benefit from the latest advances in regenerative medicine.
- Differentiation potential — they can become various cell types needed for cartilage and joint tissue maintenance.
- Immunomodulation — they can reduce harmful inflammation that drives OA progression.
- Paracrine effects — they secrete trophic factors and extracellular vesicles (including exosomes) that enhance local healing.
At the biochemical level, stem cells exert their therapeutic effects in osteoarthritis through a combination of differentiation, paracrine signaling, and immunomodulation. Mesenchymal stem cells (MSCs), chondrocytes, and iPSC‑derived progenitors can differentiate into chondrocytes, contributing directly to the regeneration of cartilage extracellular matrix, including type II collagen and aggrecan. In parallel, these cells secrete a variety of growth factors, cytokines, and exosomes that reduce inflammation by downregulating pro-inflammatory mediators such as IL-1β and TNF-α, while upregulating anti-inflammatory and anabolic pathways like TGF-β and IGF-1. Additionally, stem cell–derived exosomes carry microRNAs and proteins that enhance chondrocyte proliferation, inhibit apoptosis, and stimulate matrix synthesis, creating a microenvironment conducive to long-term joint repair and functional restoration.
Clinical studies on stem cells— a widely studied — have shown reductions in pain, improvements in joint function, and some evidence of cartilage regeneration in OA patients.
By combining multilineage stem cells with cutting‑edge delivery methods and personalized protocols, regenerative therapies aim to slow or reverse disease progression rather than just treat symptoms.
Types of Stem Cells Used in Osteoarthritis Treatment
While most clinics primarily utilize mesenchymal stem cells (MSCs) for osteoarthritis treatment, our practice adopts a personalized, combinatorial approach, selecting multiple cell types based on each patient’s unique profile. Factors such as pain severity, joint stiffness, extent of degenerative cartilage damage, comorbidities, and specific symptomatic patterns are carefully evaluated to determine the optimal regenerative strategy. This individualized selection allows us to tailor the bioactive cell and exosome products to the patient’s precise needs, enhancing therapeutic efficacy and supporting targeted cartilage and joint tissue restoration.
Different stem cell types have unique properties and contribute to joint support in complementary ways:
Mesenchymal Stem Cells (MSCs)
MSCs are the most widely studied cells for OA treatment. They are multipotent cells isolated from bone marrow, adipose (fat) tissue, and other tissues. MSCs can differentiate into cartilage‑forming chondrocytes, and they release anti‑inflammatory and trophic factors that support joint repair.
Induced Pluripotent Stem Cells (iPSCs)
iPSCs are adult cells reprogrammed to an embryonic‑like state. These cells offer powerful regenerative potential and can be directed to form specialized cell types such as chondrocytes with precise control. iPSCs enable personalized tissue regeneration without immune rejection when derived from the patient’s own cells.
Chondrocytes and Chondrogenic Progenitors
Direct use of chondrocytes — the cells responsible for producing cartilage matrix — or cartilage stem/progenitor cell‑derived exosomes has shown promise in supporting cartilage growth. Exosomes from these cells can enhance the migration, proliferation, and viability of resident chondrocytes, which are crucial for tissue repair.
Endothelial and Neural Stem Cells
While less commonly used than MSCs or iPSCs, endothelial cells support vascular regeneration to improve nutrient delivery to joint tissues, and neural stem cell‑derived factors can modulate pain signaling pathways. Research on the interaction between nervous system cells and joint tissues highlights an important role in controlling chronic pain and improving joint function over time.
Exosomes and Extracellular Vesicles
Exosomes are nano‑sized vesicles released by stem cells that carry proteins, RNAs, and signaling molecules. They serve as powerful mediators of tissue repair and immune modulation without the need to transplant whole cells. In osteoarthritis models, exosomes from MSCs have demonstrated the ability to increase cartilage matrix synthesis, reduce inflammatory mediators, and protect chondrocytes from apoptosis.
Clinical practice indicates that stem cell therapies for osteoarthritis achieve significant improvements in the majority of patients. Data from multiple cases show that approximately 70–85% of patients experience meaningful reductions in pain, improved joint mobility, and enhanced functional outcomes within 3–4 months post-treatment. Other biomarkers suggest that 40–60% of patients may exhibit signs of cartilage regeneration or slowed degenerative progression. Notably, the success rate is higher in early to moderate OA and in protocols that combine multiple stem cell types or adjunctive regenerative products, emphasizing the importance of personalized, targeted therapy.
Stem cell therapies in osteoarthritis aim to tackle the disease comprehensively: by regenerating cartilage, reducing inflammation, improving joint biomechanics, and enhancing function.
Cartilage Regeneration
Studies show that stem cell‑derived chondrocytes and exosomes can stimulate the production of cartilage components like type II collagen and aggrecan, which are critical for cartilage structure.
Pain Reduction and Functional Improvement
Clinical evidence indicates that intra‑articular injections of MSCs reduce pain scores and improve function compared to standard injections like hyaluronic acid.
Delay or Avoidance of Surgery
For many patients, regenerative therapy can delay or reduce the need for joint replacement surgery, especially if treatment is initiated early in the disease process.
Immunomodulation
Stem cells and exosomes modulate inflammatory pathways, which are important drivers of joint degeneration. This can lead to sustained improvements in symptoms and slower progression of joint damage.
Stages of Improvement
Patients typically report stages of improvement:
- Immediate: reduction in acute inflammation and swelling.
- Short‑Term (weeks): decreased pain, improved range of motion.
- Mid‑Term (months): enhanced joint stability, signs of cartilage matrix production in imaging or biomarkers.
- Long‑Term: durable functional gains and improved quality of life with reduced joint degeneration.
Safety is paramount in regenerative medicine. Stem cell therapies used in clinical settings follow international regulatory standards and ethical guidelines to ensure patient welfare. Most clinical studies report that treatments with allogeneic (donor) are well tolerated, with few serious adverse events observed over follow‑ups of up to several years.
Allogeneic (donor‑derived) stem cells offer several advantages over autologous (patient-derived) cells in the treatment of osteoarthritis. Donor cells are typically younger, more metabolically active, and possess higher proliferative and differentiation potential, which enhances their capacity for cartilage regeneration. In contrast, autologous cells from older or osteoarthritic patients often exhibit reduced viability, senescence, and diminished secretory activity, limiting their therapeutic effectiveness. Additionally, allogeneic stem cells can be carefully screened, standardized, and expanded under controlled conditions, ensuring consistent potency and quality, which supports more predictable and robust regenerative outcomes in joint repair.
When using advanced products such as iPSCs and exosomes, additional safeguards — including robust characterization, quality control, and manufacturing standards — help prevent unwanted cell behavior and ensure therapeutic consistency
Stem cell therapy for osteoarthritis may be considered for individuals who:
- Have early to moderate OA with persistent pain and functional impairment despite conventional treatments.
- Wish to delay or avoid joint replacement surgery.
- Are in sufficient overall health to support regenerative interventions.
- Understand realistic expectations: improvements take weeks to months and require medical evaluation and follow‑up.
A comprehensive assessment by a specialist in regenerative orthopedics is essential to determine the best protocol based on disease stage, joint location, and individual patient factors.
In advanced regenerative clinics, treatment is designed as a personalized, multimodal protocol. One effective strategy involves a combination of:
Local (Intra‑Articular) Injection
Delivering stem cells or exosomes directly into the affected joint provides targeted regenerative stimuli, increasing the likelihood of cartilage engagement and local tissue repair.
Intravenous (IV) Administration
IV infusion complements local therapy by supporting systemic immunomodulation and paracrine effects, circulating bioactive factors that can enhance overall healing and reduce systemic inflammation.
Rationale for Combination
The combined IV + local approach ensures that:
- Stem cells and exosomes reach both local joint environments and broader tissue repair pathways.
- Immune and inflammatory regulation is supported systemically.
- Joint microenvironment is optimized for regeneration.
Protocols may also include other biobank products that support tissue health. This multimodal strategy aligns with evidence showing that stem cell therapies involving multiple mechanisms — differentiation, trophic signaling, immunomodulation — yield more pronounced and lasting results.
PREPERE AN INDIVIDUAL TREATMENT PLAN
Recovery following stem cell therapy for osteoarthritis occurs in progressive stages, each associated with specific biochemical and functional changes:
1. Early Stage (0–4 weeks): Anti-inflammatory and Pain Modulation
Immediately after treatment, stem cells and their secreted factors, including exosomes, cytokines, and growth factors, reduce local inflammation by downregulating pro-inflammatory mediators such as IL-1β, TNF-α, and MMPs (matrix metalloproteinases). Patients often report decreased pain and swelling, improved comfort during daily activities, and reduced joint stiffness.
2. Intermediate Stage (4–12 weeks): Cellular Activation and Matrix Synthesis
During this phase, stem cells begin to interact with resident chondrocytes and synovial cells, secreting anabolic factors such as TGF-β, IGF-1, and FGF-2, which stimulate collagen type II and aggrecan synthesis. Biochemically, there is increased cartilage matrix deposition, enhanced chondrocyte proliferation, and inhibition of apoptosis. Clinically, patients may notice improved joint mobility, increased range of motion, and reduced morning stiffness.
3. Late Stage (3–6 months): Tissue Remodeling and Functional Restoration
At this stage, newly synthesized cartilage integrates with existing tissue, and extracellular matrix remodeling continues. Stem cell–derived exosomes and paracrine signals support angiogenesis and microenvironment stabilization, improving nutrient delivery and tissue homeostasis. Patients experience sustained pain relief, enhanced joint stability, and improved functional performance, such as walking, climbing stairs, or engaging in moderate exercise.
4. Long-Term Stage (6–12 months and beyond): Maintenance and Disease Modification
Over time, regenerative processes contribute to slowing of OA progression, with continued cartilage maintenance, reduced inflammatory signaling, and improved subchondral bone health. Biochemically, anabolic/catabolic balance shifts toward regeneration, and joint function is preserved or enhanced. Patients report long-lasting improvements in quality of life, often avoiding or delaying the need for joint replacement surgery.
Overall, the staged recovery reflects a synergistic effect of stem cell differentiation, trophic signaling, exosome-mediated molecular delivery, and immunomodulation, producing both symptomatic relief and structural joint repair.
Osteoarthritis Regenerative Treatment Protocol
Osteoarthritis is a progressive degenerative joint disease characterized by cartilage degradation, chronic inflammation, impaired joint lubrication, and structural changes in subchondral bone and surrounding tissues. Patients often experience joint pain, stiffness, reduced mobility, and gradual loss of joint function. Traditional therapies mainly focus on symptom relief through anti-inflammatory medications, physiotherapy, or surgical interventions, but they do not directly restore damaged cartilage or joint structures.
Our treatment protocol is based on a comprehensive regenerative medicine approach that aims to support cartilage repair, reduce inflammation, improve joint microcirculation, and stimulate the natural regenerative capacity of joint tissues. The therapy combines advanced cellular technologies and biologically active biobank products designed to address multiple biological mechanisms involved in osteoarthritis progression.
Diagnostic Evaluation
Before treatment begins, each patient undergoes a comprehensive diagnostic assessment to evaluate joint condition, inflammation level, and structural damage.
| Diagnostic Procedure | Purpose |
|---|---|
| Clinical consultation and medical history | Assessment of symptoms, mobility limitations, and disease duration |
| Orthopedic examination | Evaluation of joint stability and range of motion |
| MRI or joint ultrasound | Assessment of cartilage condition and structural changes |
| X-ray imaging | Identification of joint degeneration and osteophytes |
| Inflammatory laboratory markers | Evaluation of systemic inflammatory activity |
| Functional mobility tests | Assessment of joint performance and physical limitations |
The results of this evaluation allow physicians to develop an individualized regenerative treatment strategy.
Regenerative Treatment Components
Our protocol may include several regenerative therapies that target different structures within the joint environment.
| Therapy Component | Biological Role |
|---|---|
| Mesenchymal Stem Cells (MSC) | Anti-inflammatory effects, stimulation of cartilage regeneration, support of joint tissue repair |
| Stem Cell–Derived Exosomes | Cellular signaling, reduction of oxidative stress, activation of regenerative pathways |
| Induced Progenitor Cells | Support of cartilage matrix regeneration and tissue remodeling |
| Chondrocytes | Direct participation in cartilage matrix synthesis and repair |
| Endothelial Cells | Improvement of microvascular circulation and tissue oxygenation within joint structures |
These regenerative components work synergistically to influence cartilage tissue, synovial membranes, ligaments, and surrounding joint structures.
Joint Microenvironment Restoration
An important goal of regenerative therapy is the restoration of the joint microenvironment, which plays a critical role in maintaining cartilage health and normal joint function.
In osteoarthritis, the joint environment becomes disrupted due to chronic inflammation, synovial membrane activation, oxidative stress, and deterioration of extracellular matrix components. These processes lead to progressive cartilage breakdown and reduced regenerative capacity.
Regenerative therapies aim to restore a healthier joint environment by regulating inflammatory activity, stimulating chondrocyte function, improving synovial fluid quality, and supporting extracellular matrix regeneration.
Cartilage Regeneration and Tissue Repair
Cartilage regeneration is one of the key objectives of regenerative therapy. Mesenchymal stem cells and induced progenitor cells can influence the repair process through the secretion of growth factors and signaling molecules that stimulate cartilage matrix production.
Chondrocytes introduced during therapy may contribute directly to collagen type II synthesis and proteoglycan production, which are essential components of healthy cartilage tissue. Exosomes further support cellular communication and activate repair pathways that promote long-term cartilage stability.
Together, these biological mechanisms help support structural restoration within the joint.
Microcirculation and Tissue Nutrition
Healthy joint tissues require adequate blood supply to maintain proper metabolic activity and tissue repair processes. In osteoarthritis, microvascular circulation around the joint can become compromised.
Therapies involving endothelial cells and regenerative signaling factors aim to improve local vascularization, enhance oxygen delivery to tissues, and support metabolic recovery within cartilage and surrounding structures. Improved microcirculation may contribute to more efficient tissue regeneration and reduced inflammatory activity.
Treatment Process
The regenerative therapy program is performed according to an individualized treatment plan that may include several stages.
| Treatment Stage | Description |
|---|---|
| Patient evaluation | Diagnostic imaging and clinical assessment |
| Personalized treatment planning | Selection of regenerative therapy components |
| Cellular therapy procedures | Administration of regenerative cells and biological products |
| Joint environment support | Therapies aimed at improving microcirculation and tissue recovery |
| Follow-up monitoring | Clinical observation and functional evaluation |
Integrated Regenerative Approach
The key principle of this protocol is combination regenerative therapy, where different cellular technologies work together to address the complex biological processes involved in osteoarthritis. By simultaneously targeting cartilage degeneration, inflammation, vascular function, and tissue repair, this integrated approach aims to support the restoration of joint structure and improve long-term joint function.
1. Emma J., 62 years old, United Kingdom
Diagnosis: Knee osteoarthritis (Grade III), chronic pain, limited mobility
Medical Data Before Treatment: Severe cartilage loss on MRI, VAS pain score 8/10, walking distance <200 m
Treatment & Follow‑Up: Autologous mesenchymal stem cell injections into knee (follow‑up 12 months)
I had been diagnosed with moderate to severe osteoarthritis in my right knee for over 6 years. By the time I sought stem cell therapy, the cartilage was significantly worn down. Daily activities like climbing stairs or even walking to the store were painful. Traditional treatments (NSAIDs, physical therapy, hyaluronic acid injections) helped only for a short time.
After stem cell treatment, I began noticing improvements at around 10–12 weeks. Pain intensity dropped to 3–4/10 on the VAS scale, and swelling decreased noticeably. At 6 months, MRI showed evidence of increased cartilage signal and reduced bone marrow edema. I can now walk 1–1.5 km without stopping and climb stairs with minimal discomfort. My overall quality of life has dramatically improved.
2. Luca M., 55 years old, Italy
Diagnosis: Hip osteoarthritis (Grade IV), limited range of motion
Medical Data Before Treatment: Hip joint space narrowing, range of motion <50°, WOMAC score 68/96
Treatment & Follow‑Up: Allogeneic mesenchymal stem cell therapy + guided physical rehab (follow‑up 10 months)
I struggled with hip osteoarthritis for years, causing intense groin pain and stiffness. Standard painkillers became less effective over time. By the time I decided on stem cell therapy, I could barely bend or rotate my hip without sharp pain.
Two months after treatment, stiffness reduced significantly. By month 5, I regained much of my mobility; hip flexion increased to ~70°, and the WOMAC score improved to 32/96. Pain was reduced to about 2–3/10 on most days. I now exercise regularly and walk with good pace — activities I hadn’t managed comfortably in years.
3. Sophia L., 49 years old, Canada
Diagnosis: Rheumatoid arthritis (moderate), polyarticular inflammation
Medical Data Before Treatment: High RF and anti‑CCP levels, swollen joints (hands & wrists), DAS28 score 5.8
Treatment & Follow‑Up: Autologous stem cell transplant with intra‑articular and intravenous infusion (follow‑up 14 months)
I was diagnosed with rheumatoid arthritis in my early 40s. For years, I managed symptoms with DMARDs (methotrexate) and biologics, but flare‑ups remained frequent and debilitating. My wrists and finger joints were swollen, painful, and stiff every morning.
After stem cell therapy, flare‑ups became much less frequent. Within 4 months, joint swelling was visibly reduced and morning stiffness went from >60 minutes to ~10–15 minutes. My DAS28 score improved from 5.8 (high disease activity) to 2.9 (low disease activity). RF and anti‑CCP markers decreased moderately. I now engage in hobbies like gardening and tennis without daily pain.
4. Carlos D., 58 years old, Spain
Diagnosis: Knee and ankle osteoarthritis, chronic synovitis
Medical Data Before Treatment: Joint space narrowing on X‑ray, pain interfering with sleep (VAS 7/10), limited balance
Treatment & Follow‑Up: Mesenchymal stem cell injections + joint lavage (follow‑up 9 months)
My lower limb osteoarthritis caused severe pain in both knees and one ankle. I had trouble walking on uneven ground and often woke up at night due to joint pain. Physical therapy helped, but relief was temporary.
After stem cell therapy, pain started to diminish around 3 months. By 6 months, I consistently rated pain around 2/10. Night pain disappeared almost completely. I regained better balance and can stand for longer periods without discomfort. I resumed light hiking and walking my dog every day — activities I thought I had lost forever.
5. Anna K., 47 years old, United States
Diagnosis: Rheumatoid arthritis (severe, treatment‑resistant)
Medical Data Before Treatment: High DAS28 (6.2), multiple swollen joints, severe morning stiffness
Treatment & Follow‑Up: Multipotent stem cell infusions + tailored rehab (follow‑up 18 months)
My rheumatoid arthritis was severe and poorly controlled despite multiple medications, including biologics. My hands were often swollen and painful, making daily tasks like writing or cooking difficult. I experienced pronounced morning stiffness lasting over an hour.
Following stem cell therapy, joint swelling lessened at 4–5 months, and stiffness shortened to ~20 minutes. Over the course of a year, my DAS28 score dropped to 3.1 (low disease activity). Pain levels dropped from 7–8/10 to 2–3/10. I experience far fewer flare‑ups, and overall joint function has improved markedly.
6. Hiroshi T., 63 years old, Japan
Diagnosis: Shoulder osteoarthritis (moderate), rotator cuff irritation
Medical Data Before Treatment: Ultrasound: cartilage thinning, synovial inflammation; ROM limited by pain
Treatment & Follow‑Up: Autologous stem cell injection + guided PT (follow‑up 8 months)
I had chronic shoulder pain due to osteoarthritis and rotator cuff irritation, especially when lifting my arm above shoulder level. Traditional therapies provided modest relief, but the pain always returned.
After treatment, pain reduction was gradual. By month 3, nocturnal pain decreased, and shoulder range of motion expanded. At month 7–8, I could lift my arm overhead with minimal discomfort and perform daily tasks like hanging curtains and reaching high shelves without pain. My physical therapist also noted reduced synovial swelling on ultrasound.
7. Laura P., 51 years old, Australia
Diagnosis: Hand osteoarthritis (severe), basal thumb joint involvement
Medical Data Before Treatment: Thumb CMC joint erosion on X‑ray, grip strength 15 kg, pain VAS 8/10
Treatment & Follow‑Up: Stem cell therapy with micro‑fracture and injection (follow‑up 11 months)
I suffered from painful hand osteoarthritis, especially in my thumb, which made gripping objects, opening jars, and writing painful. Grip strength was low, and night pain prevented good sleep.
Post stem cell therapy, improvements were noticeable after 3 months. Pain dropped to ~3/10, and grip strength increased to 25 kg. By 9–10 months, I could perform all fine motor tasks — typing, cooking, gardening — without discomfort. X‑ray suggested slowed progression of joint erosion. I am delighted with the functional recovery.
The cost of regenerative therapy for osteoarthritis may vary depending on several factors, including the stage of joint degeneration, the number of affected joints, the duration of the disease, and the complexity of the clinical condition. Because osteoarthritis can involve different levels of cartilage damage, inflammation, and structural joint changes, our clinic follows a personalized treatment approach, where each therapy plan is developed individually based on diagnostic imaging, clinical evaluation, and the biological characteristics of the patient’s condition.
The treatment protocol may include various regenerative components such as mesenchymal stem cells, exosomes, induced progenitor cells, chondrocytes, and endothelial cells, as well as biologically active biobank products that support cartilage regeneration, improve joint microcirculation, and help restore the joint microenvironment. The selection and combination of these therapies depend on the degree of cartilage degeneration, inflammatory activity, and overall joint function.
Due to this individualized and multidisciplinary regenerative approach, the total cost of therapy typically ranges from 3,000 EUR, depending on the treatment strategy, the number of joints treated, and the combination of regenerative components included in the program.
GET FREE CONSULTATION
Medical Articles about Stem Cells Treatment:
Research in stem cell therapy for osteoarthritis is rapidly evolving, yet existing evidence shows promising outcomes:
- Mesenchymal stem cells for osteoarthritis: Recent advances — details therapeutic potential of MSCs and other cell types for cartilage regeneration: https://pubmed.ncbi.nlm.nih.gov/39801757/
- Mesenchymal stem cell therapy clinical review — clinical evidence that MSC therapy is safe and improves pain/function in osteoarthritis. https://pmc.ncbi.nlm.nih.gov/articles/PMC10298392/
- Randomized trial of BM‑MSCs vs HA — significant improvements in pain and function at one year: https://pubmed.ncbi.nlm.nih.gov/36262962/
- MSC‑derived exosomes therapeutic potential — exosomes enhance cartilage regeneration and anti‑inflammatory effects. https://www.mdpi.com/2079-7737/10/4/285
- iPSCs chondrogenic differentiation review — emerging personalized regenerative approach. https://link.springer.com/article/10.1186/s13287-024-03794-1
- Cartilage progenitor cell‑derived exosomes — facilitation of cartilage repair in OA model. https://pubmed.ncbi.nlm.nih.gov/38661437/
Is stem cell therapy safe for osteoarthritis?
Yes. Clinical trials indicate that intra‑articular stem cell injections are generally safe with minimal serious side effects in most patients.
How long until I see improvement?
Many patients notice changes in pain and mobility within 4–12 weeks, with continued progress over months. Long‑term benefits are often part of ongoing regenerative care.
Can stem cell therapy fully cure osteoarthritis?
While not a guaranteed cure, regenerative therapy can significantly slow disease progression, improve function, and potentially regenerate cartilage in many cases. Research is continuing to refine and enhance outcomes.
How many treatments will I need?
Treatment plans vary — some patients require one course of injections; others benefit from repeated sessions depending on OA severity and individual response.
On average, how long do the improvements last?
According to our patients’ statistics, on average, the effect of the therapy lasts 2–3 years (depending on the degree of joint damage). But at an early stage, the effect can last even longer.
Is it possible to avoid surgery using stem cell therapy?
Yes, it is possible. There are many cases when a patient is recommended for joint replacement, but after starting therapy, they avoid the need for surgery and even return to physical activity.